Revenue Breakdown
Composition ()
No data
Revenue Streams
Twist Bioscience Corp (TWST) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is NGS tools, accounting for 53.6% of total sales, equivalent to $53.03M. Other significant revenue streams include Synthetic genes and Antibody discovery. Understanding this composition is critical for investors evaluating how TWST navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Twist Bioscience Corp maintains a gross margin of 51.35%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -30.23%, while the net margin is -27.41%. These profitability ratios, combined with a Return on Equity (ROE) of -16.43%, provide a clear picture of how effectively TWST converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, TWST competes directly with industry leaders such as MLYS and RCUS. With a market capitalization of $2.63B, it holds a significant position in the sector. When comparing efficiency, TWST's gross margin of 51.35% stands against MLYS's N/A and RCUS's 100.00%. Such benchmarking helps identify whether Twist Bioscience Corp is trading at a premium or discount relative to its financial performance.
